checkAd
    Brainstorm Cell Therapeutics Aktie
    0,5664
     
    USD
    -1,82 %
    -0,0105 USD
    Letzter Kurs 02:00:00 NYSE
    0,5517
     
    USD
    600 STK
    Geldkurs 23.05.24
    0,5841
     
    USD
    500 STK
    Briefkurs 23.05.24
    ISIN: US10501E2019 · WKN: A12BXW · SYM: BCLI · USA

    Neueste Nachrichten

    BCLI FINAL DEADLINE NOTICE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Brainstorm Cell Therapeutics Inc. Investors with Losses in Excess of $500K to Secure Counsel Before Important January 2 Deadline in Securities Class Action Filed by the Firm
    31.12.23 · Business Wire (engl.) · Brainstorm Cell Therapeutics
    The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Brainstorm Cell Therapeutics Inc. (BCLI)
    28.12.23 · Business Wire (engl.) · Brainstorm Cell Therapeutics
    BCLI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Brainstorm Cell Therapeutics Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
    20.11.23 · Business Wire (engl.) · Brainstorm Cell Therapeutics
    Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Brainstorm Cell Therapeutics Inc. (BCLI)
    14.11.23 · Business Wire (engl.) · Brainstorm Cell Therapeutics
    BCLI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Brainstorm Cell Therapeutics Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
    14.11.23 · Business Wire (engl.) · Brainstorm Cell Therapeutics
    Brainstorm Cell Therapeutics Inc. (BCLI) Investors: Shareholders with Large Losses Should Contact Robbins LLP Regarding the BCLI Class Action
    14.11.23 · Business Wire (engl.) · Brainstorm Cell Therapeutics
    Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Brainstorm Cell Therapeutics Inc. (BCLI)
    13.11.23 · Business Wire (engl.) · Brainstorm Cell Therapeutics
    Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Brainstorm Cell Therapeutics Inc. (BCLI) Investors
    08.11.23 · Business Wire (engl.) · Brainstorm Cell Therapeutics
    The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Brainstorm Cell Therapeutics Inc. (BCLI) Investors
    07.11.23 · Business Wire (engl.) · Brainstorm Cell Therapeutics
    INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Brainstorm Cell Therapeutics Inc. (BCLI) Investors
    07.11.23 · Business Wire (engl.) · Brainstorm Cell Therapeutics
    Brainstorm Cell Therapeutics Inc. (BCS) Investor Notice: Robbins LLP Reminds Investors of Class Action Against Brainstorm Cell Therapeutics Inc.
    06.11.23 · Business Wire (engl.) · Brainstorm Cell Therapeutics
    Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Brainstorm Cell Therapeutics Inc. (BCLI) on Behalf of Investors
    06.11.23 · Business Wire (engl.) · Brainstorm Cell Therapeutics